Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | PHGDH | O43175 | 2/20 | 0.45 |
| ▸ | HCAR3 | P49019 | 4/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10022424 | 0.87 | KDM4E (0.55) | KDM4EPHGDHHPGDALDH1A1HSD17B10 | |
| SCHEMBL23809378 | 0.87 | KDM4E (0.44) | KDM4EPHGDHHCAR3HPGDHCAR2 | |
| SCHEMBL7877815 | 0.82 | HCAR3 (0.47) | KDM4EHCAR3HPGDHCAR2SMN1; SMN2 | |
| SCHEMBL3987986 | 0.79 | KDM4E (0.55) | KDM4EHCAR3HPGDALDH1A1HSD17B10 | |
| SCHEMBL30622485 | 0.79 | KDM4E (0.55) | KDM4EHCAR3HPGDALDH1A1HSD17B10 | |
| SCHEMBL5889548 | 0.79 | KDM4E (0.68) | KDM4EPHGDHHCAR3HPGDALDH1A1 | |
| SCHEMBL28143548 | 0.78 | KDM4E (0.49) | KDM4EPHGDHHCAR3HPGDALDH1A1 | |
| SCHEMBL28323883 | 0.78 | HCAR3 (0.49) | KDM4EPHGDHHCAR3HPGDHCAR2 | |
| SCHEMBL28264561 | 0.78 | MCL1 (0.53) | KDM4EPHGDHHCAR3HPGDALDH1A1 | |
| SCHEMBL27880258 | 0.78 | KDM4E (0.53) | KDM4EPHGDHHCAR3HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210283138-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2021-09-16 | — | — | US | disclosed |
| US-20120065196-A1 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210283138-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, BCL9 | KDM4E 1156/4885PHGDH 2796/4885HCAR3 4325/4885 |
| US-20120065196-A1 | AMIDE COMPOUNDS | DGAT2, DGAT1, DLAT | KDM4E 2452/4885PHGDH 303/4885HCAR3 1993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.